Gemini Space Station (NASDAQ:GEMI) shares rose about 5% on Friday after the company reported first quarter financial results that came in ahead of Wall Street expectations, alongside a new strategic investment that underscored continued expansion beyond core crypto trading.
The company reported a net loss of $0.93 per share for the quarter ended March 31, compared with analyst expectations of a $1.07 per-share loss.
POET Technologies Inc (TSX-V:PTK, NASDAQ:POET, FRA:RI4A) stock fell about 12% on Friday following the announcement of a $400 million registered direct offering and weaker-than-expected first quarter earnings.
The company, which designs and develops Photonic Integrated Circuits (PICs), light sources and optical modules for the AI and data center market, said on Friday that it has entered into a definitive agreement to issue and sell about 19 million common shares and warrants exercisable for an additional approximately 19 million shares to a single institutional investor in a non-brokered registered direct offering.
Billionaire investor Bill Ackman said his hedge fund, Pershing Square Capital Management, has initiated a new position in Microsoft Corp (NASDAQ:MSFT), according to a post on the social media platform X ahead of an upcoming 13F filing.
“As two of the largest forces in equity markets -- growing index ownership and increasing amounts of capital controlled by extremely short-term-oriented, leveraged, volatility-intolerant investors -- converge, we have found occasional opportunities to acquire some of the most dominant long-term compounding franchises at attractive valuations,” Ackman wrote.
Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF) shares jumped 46% to 1.74p after the AIM-listed critical metals developer expanded its agreement with DISA Technologies to evaluate and potentially treat abandoned uranium mine waste dumps at its Uravan Belt project in Colorado.
The deal covers eight separate waste dumps across the 490-hectare site near the historic Buckhorn Mine.
ValiRx, the AIM-listed life sciences company focused on early-stage cancer therapeutics and women's health, has raised up to £1.155 million through a placing, subscription, and planned retail offer at 0.2p per share.
The shares fell 17% to 0.2p, matching the issue price, which itself represented a 17% discount to the previous closing price.